Igenesis
iGenesisBio (奥然生物) develops fully automated nucleic acid detection and analysis systems. The company's Galaxy system, comprising the iCassette smart box and Galaxy series instruments, intelligently completes the full process from sample nucleic acid extraction and purification through fluorescence PCR amplification and analysis in an integrated, fully closed system. iGenesisBio offers instruments including Galaxy…
Funding snapshot
About
iGenesisBio (奥然生物) develops fully automated nucleic acid detection and analysis systems. The company's Galaxy system, comprising the iCassette smart box and Galaxy series instruments, intelligently completes the full process from sample nucleic acid extraction and purification through fluorescence PCR amplification and analysis in an integrated, fully closed system. iGenesisBio offers instruments including Galaxy Nano, Galaxy Lite, and Universal Pro with varying sample throughputs, along with detection reagents for intestinal diseases, sexually transmitted diseases, respiratory diseases, and vector-borne infectious diseases. The company provides solutions for hospitals, disease control centers, entry-exit inspection and quarantine, and forensic identification, with strong instrument and reagent development and production capabilities. Founded in 2015, headquartered in Shanghai, China, The company has raised $13.0M at the Series C stage, backed by investors including Shenzhen Capital Group, Shenzhen Qianhai Bangqin Investment, Shanghai Kehua Bio-engineering, Morningside, Silicon Harbour Capital..
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Amplification-based > PCR,
Life Sciences Platforms and Tools > Instruments > Genomics > PCR
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.